RELMADA THERAPEUTICS, INC. Accrued Liabilities, Current
RELMADA THERAPEUTICS, INC. (RLMD) had Accrued Liabilities, Current of $5.01 million as of 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Balance Sheet › Liabilities › Liabilities, Current › Accounts Payable and Accrued Liabilities, Current
us-gaap:AccruedLiabilitiesCurrent · last filed 2026-08-06
- 2026-06-30: Accrued Liabilities, Current $5.01M.
- 2026-03-31: Accrued Liabilities, Current $7.16M.
- 2025-12-31: Accrued Liabilities, Current $4.86M.
- 2025-09-30: Accrued Liabilities, Current $3.74M.
| Period end | Accrued Liabilities, Current |
|---|---|
| 2026-06-30 | $5.01M 10-Q · filed 2026-08-06 |
| 2026-03-31 | $7.16M 10-Q · filed 2026-05-12 |
| 2025-12-31 | $4.86M 10-Q · filed 2026-08-06 |
| 2025-09-30 | $3.74M 10-Q · filed 2025-11-13 |
| 2025-06-30 | $3.77M 10-Q · filed 2025-08-07 |
| 2025-03-31 | $3.97M 10-Q · filed 2025-05-12 |
| 2024-12-31 | $6.16M 10-K · filed 2026-03-19 |
| 2024-09-30 | $5.74M 10-Q · filed 2024-11-07 |
| 2024-06-30 | $5.36M 10-Q · filed 2024-08-07 |
| 2024-03-31 | $7.17M 10-Q · filed 2024-05-08 |
| 2023-12-31 | $8.69M 10-K · filed 2025-03-27 |
| 2023-09-30 | $5.57M 10-Q · filed 2023-11-08 |
| 2023-06-30 | $5.85M 10-Q · filed 2023-08-08 |
| 2023-03-31 | $5.68M 10-Q · filed 2023-05-11 |
| 2022-12-31 | $7.21M 10-K · filed 2024-03-19 |
| 2022-09-30 | $10.35M 10-Q · filed 2022-11-10 |
| 2022-06-30 | $11.38M 10-Q · filed 2022-08-11 |
| 2022-03-31 | $4.74M 10-Q · filed 2022-05-05 |
| 2021-12-31 | $3.87M 10-K · filed 2023-03-23 |
| 2021-09-30 | $5.54M 10-Q · filed 2021-11-12 |
| 2021-06-30 | $3.46M 10-Q · filed 2021-08-10 |
| 2021-03-31 | $4.64M 10-Q · filed 2021-05-12 |
| 2020-12-31 | $4.26M 10-K · filed 2022-03-25 |
| 2020-09-30 | $2.66M 10-Q · filed 2020-11-12 |
| 2020-06-30 | $1.36M 10-Q · filed 2020-08-12 |
| 2020-03-31 | $1.16M 10-Q · filed 2020-05-15 |
| 2019-12-31 | $824.94K 10-K · filed 2021-03-24 |
| 2019-09-30 | $1.01M 10-Q · filed 2019-11-13 |
| 2019-06-30 | $1.32M 10-K · filed 2021-03-24 |
| 2019-03-31 | $1.02M 10-Q · filed 2019-05-15 |
| 2018-12-31 | $1.39M 10-Q · filed 2019-02-13 |
| 2018-09-30 | $966.16K 10-Q · filed 2018-11-13 |
| 2018-06-30 | $659.46K 10-KT · filed 2020-03-26 |
| 2018-03-31 | $458.58K 10-Q · filed 2018-05-14 |
| 2017-12-31 | $494.10K 10-Q · filed 2018-02-12 |
| 2017-09-30 | $407.31K 10-Q · filed 2017-11-14 |
| 2017-06-30 | $394.56K 10-K · filed 2018-09-28 |
| 2017-03-31 | $586.44K 10-Q · filed 2017-05-15 |
| 2016-12-31 | $472.48K 10-Q · filed 2017-02-10 |
| 2016-09-30 | $404.89K 10-Q · filed 2016-11-10 |
| 2016-06-30 | $634.85K 10-K · filed 2017-09-28 |
| 2016-03-31 | $1.05M 10-Q · filed 2016-05-09 |
| 2015-12-31 | $1.56M 10-Q · filed 2016-02-05 |
| 2015-09-30 | $614.53K 10-Q · filed 2015-11-06 |
| 2015-06-30 | $482.27K 10-K · filed 2016-09-09 |
| 2015-03-31 | $398.49K 10-Q · filed 2015-05-15 |
| 2014-12-31 | $521.68K 10-Q · filed 2015-02-13 |
| 2014-09-30 | $879.50K 10-Q · filed 2014-11-07 |
| 2014-06-30 | $382.02K 10-K · filed 2015-09-11 |
| 2014-03-31 | $164.52K 8-K · filed 2014-05-27 |
| 2013-12-31 | $438.66K 10-KT · filed 2014-09-09 |
| 2012-12-31 | $222.95K 8-K · filed 2014-05-27 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Opus Genetics, Inc. (IRD) | United States | $0.406B | -3.16 |
| Arcturus Therapeutics Holdings Inc. (ARCT) | $0.402B | -2.05 | |
| GALECTIN THERAPEUTICS INC (GALT) | United States | $0.399B | -11.06 |
| ARS Pharmaceuticals, Inc. (SPRY) | United States | $0.414B | -3.70 |
| Atea Pharmaceuticals, Inc. (AVIR) | United States | $0.414B | -2.26 |
| Turn Therapeutics Inc. (TTRX) | United States | $0.397B | -25.68 |
| DiaMedica Therapeutics Inc. (DMAC) | United States | $0.423B | -10.11 |
| PROTHENA CORP PUBLIC LTD CO (PRTA) | Ireland | $0.428B | -11.53 |
| Rezolute, Inc. (RZLT) | United States | $0.382B | -6.45 |
| CYPHERPUNK TECHNOLOGIES INC. (CYPH) | United States | $0.438B | -75.63 |